At the Extraordinary General Meeting of Infant Bacterial Therapeutics AB (publ) on June 9, 2023, it was resolved to approve the Board of Directors&rsquo...
Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in Stockholm, gives notice of the Extraordinary General Meeting...
2023-05-16 23:00 IBT resolves on a rights issue Regulatory MAR
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA...
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 8, 2023, among other things, the following was resolved: implementation...
Message from the CEO Significant advancements have been made in the development of microbiome-based pharmaceuticals in the past few months. Ferring/Rebiotics'...
Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in Stockholm, gives notice of the Annual General Meeting to be...
Infant Bacterial Therapeutics AB (publ) publishes today the Annual Report for 2022. The report is available on IBT´s website, ibtherapeutics.com...
IBT is pleased to announce today's opening of the additional cohort, having included 1,400 premature infants of the total 2,158 recruitment target. Up...
Message from the CEO The speed of recruitment of preterm infants into our large phase 3 study significantly increased in the final three months of 2022...
On March 31 2022 IBT published the 2021 annual report in the format of a PDF file. Today, IBT publish the same report in the XHTML format. The content...

Subscribe to our press releases